Launched or under launch (2013-2015): Australia, Austria, Canada, Chile, Colombia, Denmark,Egypt, Israel, Jordan, Malaysia, Middle East, Montenegro, New Zealand, Romania, Serbia, South Africa, Spain, Tunisia.
HERPECILIN – Labial Herpes
6mL (tube) Class IIa Medical Device for the treatment of open Labial Herpes lesions (Official Indication)
LABIAL HERPES (Cold sore, Herpes Simplex Labialis)
Physiopathology: After initial infection, HSV1 ascends nerve axons & remains latent in the ganglia, until it gets activated by a trigger & migrates to the skin and mucosa surface. A vesicle develops where the virus multiplies. The open lesion then sheds large amounts of free virus particles which infect new host cells, spreading the infection & lesions, resulting in cellular destruction, inflammation, pain & burning sensation.
Ideal Treatment Approach: An ideal treatment should stop virus activation, but such a treatment should be administered as soon as the virus is activated. Oral Acyclovir may be a good antiviral but should be administered before the virus reaches oral mucosa (preventive treatment).
Currently Available Treatments:
- Topical Anti-Viral: none
- Intracellular Virus inhibitors: Acyclovirs such as Zovirax, etc… → Good as preventive but not effective at all on free virus.
- Symptomatic: topical anesthetics, antiseptics, analgesics, protective or hydrating films.
None of these treatments is capable of neutralizing the virus & stopping further infection, blocking inflammation & pain, or stimulating instant lesion healing so as to minimize pain & irritation.
VITROBIO‘s Completely NEW Therapeutic Approach: Anti-protein Hypothesis to block virus growth & inflammation
HSV1 is an enveloped Virus with several Glycoproteins (GPs) on its surface (gB, gA, gC) which allow virus entry into the host cells. Vitrobio postulated that these virus proteins could be blocked & new virus infection could be stopped using specific virus protein antagonist polymers (Ref: Hypothesis – Shrivastava et al: Int. J. Virology, 2011). Similarly, bacterial infection can also be stopped by neutralizing bacterial fibronectins with polymers capable of binding with macromolecules. Inflammation & pain can also be reduced by blocking specifically the pro-inflammatory proteins (cytokines).
After 17 years of R&D, Vitrobio identified specific polymers which can bind with selected targets & neutralize the infection (Patent PCT/EP2010/050236). These polymers were then incorporated into a patented glycerol-based filmogen viscous solution, glycerol being commonly used as pharmaceutical excipient & 18 times more osmotically active than Sea Water yet NON-IRRITANT (International patents: PCT/FR99/01340 & PCT/EP2013/061835). The hypertonic solution film attracts hypotonic fluids from the lesion surface and dislodges all contaminants, reduces pain & irritation and promotes a clean, favorable environment conducive to accelerated lesion healing. Due to instant the mechanical effects consisting in neutralizing the infection, cleaning & protecting the sore, lesion healing & symptomatic relief are very fast. Herpecilin is the 1st, topical, safe, topical anti-viral & anti-inflammatory new generation of cold sore treatment.
Product Presentation: 6mL tube
Posology: Apply a few drops on the lesion, 3 to 4 times a day until complete recovery.
Regulatory Status: Due to the mechanical topical filmogen activity without any pharmacological, biological, metabolic or immunological interaction with the cellular structure: Class IIa Medical Device in Europe.
Side Effects: None
Clinical Efficacy: Full trial published in Int J Biological & Pharmaceutical Res. 2013; 4(4): 242-249; e-ISSN: 0976-3651.
Conclusion: 1st topical Anti-Viral & Healing Gel for Cold Sores